In vitro susceptibility of clinical isolates of Candida kefyr
Abstract number: R2461
Gomez-Lopez A., Pan D., Rodriguez-Tudela J.L., Cuenca-Estrella M.
Background: Several surveillance programmes in Europe and USA have detected an increase in the prevalence of fungal infections caused by Candida species other than Candida albicans. Among these species, C. kefyr has been reported recently as an a possible emerging pathogen. We have reviewed the antifungal susceptibility profile of the collection of clinical isolates of C. kefyr in order to give any insight on the management of this pathogen.
Methods: A total of 34 isolates of C. kefyr received in our institution between 1995 and 2007 was evaluated. The isolates were identified by routine physiological tests. The MICs of amphotericin B (AMB), flucytosine (5-FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), ravuconazole (RVC), posaconazole (POS), caspofungin (CAS), micafungin (MCF) and anidulanfungin (AND) were determined according to the recommendations proposed by the European Committee on Antifungal Susceptibility Testing for fermentative yeast (EUCAST-definitive document).
Results: Of the 34 strains, a total of 26.5% was isolated from blood cultures, 17.6 from vaginal exudates, 14.7% from oropharyngeal exudates, and 29.4% from other sites. A high number of isolates were received in the last four years (19/34, 55.8% since 2004). All of the strains were considered sensitive to AMB (Geometric Mean, GM, 0.22 mg/L and MIC range: 0.061 mg/L). Of note, three isolates exhibited an AMB MIC=1 mg/L. Only one isolate was resistant in vitro to flucytosine (MIC 32 mg/L). All the azole compounds showed great activity against C. kefyr isolates, with GM values of 0.25, 0.029, 0.015, 0.024 and 0.015 for FLC, ITC, VRC, RVC and POS respectively. In addition, echinocandins demonstrated excellent activity against all of the strains tested. (MIC values lower than 0.12 mg/L)
Conclusions:C. kefyr seems to be an emerging pathogen. Most of isolates are susceptible in vitro to all antifungal agents currently licensed.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|